EPPK1 and colon adenocarcinoma: The inclusion of adenoma cases in our study allowed for a comprehensive assessment of carcinogenesis stages, revealing a consistent decrease in epiplakin expression across both colon adenocarcinoma and tubulovillous adenomas (high malignancy risk group) (P < 0.05).